Evidence map›Paper›PMID 42877143›Full record

ArticleFrontiers in reproductive health2026

Comparative outcomes of conventional follitropin delta 15 µg/day versus follitropin alfa 225 IU/day for ovarian stimulation: results from an exploratory

Marta García Sánchez, Andrea Bernabeu, Ana Hernández Cesteros, Laura Blasco Gastón, Sofia Ortega Ricondo, Gemma Castillón, Marcos Ferrando Serrano, Signe Møgelmose, Enrica Gravotta, Rita Lobo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marta García SánchezIVIRMA Global Research Alliance, IVIRMA, Málaga, Spain.
Andrea BernabeuInstituto Bernabeu Alicante, Albufereta, Alicante, Spain.
Ana Hernández CesterosVida Recoletas Salud, Valladolid, Spain.
Laura Blasco GastónGinefiv, Madrid, Spain.
Sofia Ortega RicondoHospital Universitario Principe De Asturias, Madrid, Spain.
Gemma CastillónIVI, Barcelona, Spain.
Marcos Ferrando SerranoIVIRMA Global Research Alliance, IVIRMA, Bilbao, Spain.
Signe MøgelmoseGlobal Biometrics, Ferring Pharmaceuticals, Kastrup, Denmark.
Enrica GravottaGlobal Research and Medical, Ferring Pharmaceuticals, Kastrup, Denmark.
Rita LoboGlobal Research and Medical, Ferring Pharmaceuticals, Kastrup, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research question: Can follitropin delta be used in a conventional regimen (15 µg/day starting dose) without compromising efficacy and safety in patients seeking fertility treatment in Spain? Design: This was an exploratory Results: A total of 132 patients were randomized (10-AUG-2022 to 11-MAR-2024): follitropin delta group, Conclusions: Our exploratory analysis shows that a higher starting dose of follitropin delta 15 µg/day in a conventional regimen can be successfully used in appropriately selected infertile patients, resulting in a good average oocyte yield without compromising first-transfer clinical pregnancy rates and while maintaining a low incidence of early OHSS.

Indexed as

conventional dosing regimenFE999049follitropin deltagonadotropinsnormo-respondersovarian stimulationrFSH

Identifiers

PMID42877143
PMCPMC13662129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.